LONDON - Patients involved in early tests of a Russian coronavirus vaccine developed antibodies with "no serious adverse events", according to research published in The Lancet Friday, but experts said
LONDON - Patients involved in early tests of a Russian coronavirus vaccine developed antibodies with "no serious adverse events", according to research published in The Lancet Friday, but experts said the trials were too small to prove safety and effectiveness.
Each participant was given a dose of the first part of the vaccine and then given a booster with the second part 21 days later. The report said the data showed that the vaccine was "safe, well tolerated, and does not cause serious adverse events in healthy adult volunteers". The report said the 76 participants of these trials would be monitored up to 180 days, adding that a more rigorous phase 3 clinical trial was planned with the involvement of 40,000 volunteers "from different age and risk groups".
The pandemic has seen an unprecedented mobilization of funding and research to rush through a vaccine that can protect billions of people worldwide.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Russia vaccine 'passes early trial test'Researchers underline that larger and longer trials – including a placebo comparison – would be needed to establish the long-term safety and effectiveness of the vaccine for preventing COVID-19 infection.
Read more »
Russia vaccine 'passes early trial test'Researchers underline that larger and longer trials – including a placebo comparison – would be needed to establish the long-term safety and effectiveness of the vaccine for preventing COVID-19 infection.
Read more »
Widespread COVID-19 vaccination not likely available until mid-2021, World Health Organization saysThere are currently 34 vaccines globally carrying out human trials, according to WHO, with 142 vaccine candidates currently in the pre-clinical trial phase
Read more »
Novavax coronavirus vaccine is safe, published results showEarly stage clinical trial results show the Covid-19 vaccine candidate made by Novavax is safe and elicits an immune response, according to a study published in The New England Journal of Medicine.
Read more »
DOH stops Cavite vaccine trial pending approvalSome 10,000 residents in Cavite cannot take part in clinical trials for a potential vaccine against COVID-19 without the approval of the FDA and an ethics review board, Vergeire said. | jovicyeeINQ
Read more »
Pfizer's COVID-19 vaccine trial should have enough data to know if it works by end of October, CEO saysPfizer Chairman and Chief Executive Officer Dr. Albert Bourla said the ongoing clinical trial for a COVID-19 vaccine has enrolled about 23,000 participants, and some are already getting the second dose of the vaccine.
Read more »